Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress

Stock Track

Feb 28

AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.

The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.

AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.

Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1157205544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157205544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157205544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157205544","market":"us","top_or_hot":-1,"title":"Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress","media":"Stock Track","content":"<p>AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.</p>\n\n<p>The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.</p>\n\n<p>AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.</p>\n\n<p>Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.</p>\n\n<p>The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.</p>\n\n<p>AbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.</p>\n\n<p>Other key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1157205544","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157205544","pubTimestamp":1740753761,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics  stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.The biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.AbCellera announced that its two lead antibody","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"尽管管道取得进展，AbCellera股价在2024年跌幅扩大后盘前暴跌16.78%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics (ABCL) stock plummeted 16.78% in pre-market trading on Friday, following the company's fourth-quarter and full-year 2024 financial results released during the pre-market session.\nThe biotech firm reported a wider net loss of roughly $163 million for the full year 2024, compared to a loss of about $146 million in the previous year. Despite the increased loss, AbCellera made progress in advancing its internal drug pipeline during the year.\nAbCellera announced that its two lead antibody programs, ABCL635 and ABCL575, are positioned for clinical trial application (CTA) filings in the second quarter of 2025. The company has a robust portfolio of more than 20 preclinical programs behind these lead candidates.\nOther key highlights from AbCellera's 2024 performance include completing its move into a new headquarters, being on track to bring its clinical manufacturing facility online in 2025, and entering into a new partnership with AbbVie to leverage its T-cell engager (TCE) platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}